ICD-10 C72.30 is officially defined as "Malignant neoplasm of unspecified optic nerve." code C72.30 is referenced in 3 tracked payer policy changes from Blue Cross Blue Shield of North Dakota, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code C72.30 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Blue Cross Blue Shield of North Dakota has updated multiple pharmacy prior authorization policies for specialty medications, with new requirements effective October 1, 2025 for Datopotamab deruxtecan-dlnk (Datroway) and revised policies for various oncology drugs effective November 1, 2025. These changes affect prior authorization criteria, step therapy requirements, and billing codes for high-cost specialty medications.
Aetna's Clinical Policy Bulletin 0013 sets medical necessity criteria for cochlear implants and auditory brainstem implants. Adults with bilateral sensorineural moderate-to-profound hearing impairment need a pure-tone average of 60 dB HL or greater at 500, 1000 and 2000 Hz, limited benefit from appropriately fitted hearing aids, and a hearing aid trial of at least 30 days worn full time, while children need a pure-tone average of 70 dB HL or greater at those frequencies and limited benefit from appropriately fitted binaural hearing aids. Cochlear implantation for auditory dyssynchrony, auditory neuropathy spectrum disorder, tinnitus and all other indications not meeting these criteria is considered experimental, investigational or unproven.
Genetic testing for NF1 or NF2 pathogenic variants may be considered medically necessary when a diagnosis of neurofibromatosis is clinically suspected due to signs of disease but a definitive diagnosis cannot be made without genetic testing. Genetic testing for NF1 or NF2 pathogenic variants in at-risk relatives with no signs of disease may be considered medically necessary when a definitive diagnosis cannot be made without genetic testing and a close relative (first-, second- or third-degree) has a known NF1 or NF2 variant or has been diagnosed with neurofibromatosis but whose genetic status is unavailable. Genetic testing for neurofibromatosis in all other situations is considered investigational.
Watch C72.30
Get one email when a payer policy names C72.30, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.